0.225
price down icon0.04%   -0.000100
after-market Dopo l'orario di chiusura: .24 0.015 +6.67%
loading
Precedente Chiudi:
$0.2251
Aprire:
$0.2291
Volume 24 ore:
354.80K
Relative Volume:
0.33
Capitalizzazione di mercato:
$10.33M
Reddito:
-
Utile/perdita netta:
$-21.46M
Rapporto P/E:
-0.0888
EPS:
-2.5324
Flusso di cassa netto:
$-14.40M
1 W Prestazione:
+3.93%
1M Prestazione:
-11.07%
6M Prestazione:
-2.13%
1 anno Prestazione:
-45.86%
Intervallo 1D:
Value
$0.225
$0.2377
Intervallo di 1 settimana:
Value
$0.21
$0.2391
Portata 52W:
Value
$0.1628
$0.8632

Theriva Biologics Inc Stock (TOVX) Company Profile

Name
Nome
Theriva Biologics Inc
Name
Telefono
301 417 4364
Name
Indirizzo
9605 Medical Center Drive, Suite 270, Rockville
Name
Dipendente
21
Name
Cinguettio
Name
Prossima data di guadagno
2026-11-11
Name
Ultimi documenti SEC
Name
TOVX's Discussions on Twitter

Compare TOVX vs VRTX, MRNA, REGN, ARGX, RVMD

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
TOVX icon
TOVX
Theriva Biologics Inc
0.225 10.12M 0 -21.46M -14.40M -2.5324
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
503.50 127.93B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
203.21 79.40B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
726.47 81.13B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
912.87 60.03B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
207.68 43.93B 742.00K -1.37B -1.07B -7.0731

Theriva Biologics Inc Borsa (TOVX) Ultime notizie

pulisher
Sep 30, 2026

Theriva™ Biologics anuncia la publicación en Nature Medicine de los resultados del ensayo clínico de Fase 2b VIRAGE con VCN-01 en el cáncer de páncreas metastásico - GlobeNewswire Inc.

Sep 30, 2026
pulisher
Sep 30, 2026

Theriva publishes VCN-01 pancreatic cancer trial data in journal By Investing.com - Investing.com Canada

Sep 30, 2026
pulisher
Sep 30, 2026

Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine - Yahoo! Finance Canada

Sep 30, 2026
pulisher
Sep 26, 2026

TOVX Should I Buy - Intellectia AI

Sep 26, 2026
pulisher
Sep 04, 2026

Theriva Biologics Inc. (TOVX) Peer Comparison – Compare with Others - Value Research

Sep 04, 2026
pulisher
Aug 31, 2026

Theriva Biologics Inc. (TOVX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

Aug 31, 2026
pulisher
Aug 31, 2026

Theriva Biologics Inc. (TOVX) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research

Aug 31, 2026
pulisher
Aug 27, 2026

Theriva Biologics Inc. (TOVX) Key Financial Ratios – Valuation, Profitability & More - Value Research

Aug 27, 2026
pulisher
Aug 19, 2026

Theriva (TOVX) Earnings Report: The Available Figures Are Largely Near Expectations; Post-Report: The Stock Finishes Near Unchanged on the DayConsensus Beat Rate - vinanet.vn

Aug 19, 2026
pulisher
Aug 18, 2026

Theriva Biologics(TOVX) Stock Options Chain | Quotes & News - Moomoo

Aug 18, 2026
pulisher
Aug 16, 2026

Theriva Biologics (TOVX) Edges Down 0.87% to $0.23, Holding Above SupportRounding Bottom - vinanet.vn

Aug 16, 2026
pulisher
Aug 14, 2026

Theriva Biologics (TOVX) Holds at $0.23 as Micro-Cap Biotech Tests Key Support ZoneQuality Factor - vinanet.vn

Aug 14, 2026
pulisher
Aug 13, 2026

Theriva Biologics (TOVX) Dips 4.17% to $0.23 as Micro-Cap Biotech Holds Above $0.22 SupportSentiment Divergence - vinanet.vn

Aug 13, 2026
pulisher
Aug 12, 2026

Maxim Group Maintains Theriva Biologics(TOVX.US) With Buy Rating, Maintains Target Price $1 - Moomoo

Aug 12, 2026
pulisher
Aug 11, 2026

Theriva Biologics Releases Q2 2026 Financial Results - AlphaStreet

Aug 11, 2026
pulisher
Aug 11, 2026

Form 8K Theriva Biologics Inc For: 11 August By Investing.com - Investing.com Nigeria

Aug 11, 2026
pulisher
Aug 11, 2026

Theriva Biologics, Inc. 2026: Revenue ($3.35M), Net income ($3.22M), EPS ($0.07) — 10-Q Summary - TradingView

Aug 11, 2026
pulisher
Aug 11, 2026

Theriva Biologics reports $3.2 million Q2 loss and VCN-01 dosing progress - Quiver Quantitative

Aug 11, 2026
pulisher
Aug 11, 2026

Theriva Biologics reports Q2 2026 results; $11.3M cash, net loss $3.2M for quarter - TradingView

Aug 11, 2026
pulisher
Aug 11, 2026

Theriva Biologics (NYSE American: TOVX) narrows Q2 loss, advances VCN-01 trial - Stock Titan

Aug 11, 2026
pulisher
Aug 11, 2026

Theriva Biologics: Q2 Earnings Snapshot - marketscreener.com

Aug 11, 2026
pulisher
Aug 11, 2026

Theriva Biologics 2Q Loss/Shr 7c >TOVX - Moomoo

Aug 11, 2026
pulisher
Aug 11, 2026

BRIEF-Theriva Biologics Q2 Net Income USD -3.217 Million - TradingView

Aug 11, 2026
pulisher
Aug 11, 2026

Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results - GlobeNewswire

Aug 11, 2026
pulisher
Aug 07, 2026

Theriva Biologics Inc (TOVX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Aug 07, 2026
pulisher
Aug 06, 2026

Theriva doses first patient in VCN-01 pancreatic cancer trial By Investing.com - Investing.com South Africa

Aug 06, 2026
pulisher
Aug 06, 2026

Theriva Biologics Doses First Patient in VIRAGE2 Phase 2a Trial to Refine VCN-01 Therapy for Metastatic Pancreatic Cancer – Minichart - Minichart

Aug 06, 2026
pulisher
Aug 06, 2026

Form 8K Theriva Biologics Inc For: 6 August By Investing.com - Investing.com Nigeria

Aug 06, 2026
pulisher
Aug 06, 2026

Theriva Biologics (NYSE American: TOVX) starts VIRAGE2 Phase 2a trial in PDAC - Stock Titan

Aug 06, 2026
pulisher
Aug 06, 2026

Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 - GlobeNewswire

Aug 06, 2026
pulisher
Aug 04, 2026

Theriva Biologics Expands Stock Incentive and Governance Plans - TipRanks

Aug 04, 2026
pulisher
Aug 04, 2026

Theriva Biologics (NYSE American: TOVX) holders back bigger stock plan, warrants - Stock Titan

Aug 04, 2026
pulisher
Aug 01, 2026

Theriva Biologics, Inc. Revenue Breakdown – AMEX:TOVX - TradingView

Aug 01, 2026
pulisher
Jul 30, 2026

TOVX|Theriva Biologics Inc|Price:0.222|Chg%:+0.012 - TradingKey

Jul 30, 2026
pulisher
Jul 27, 2026

Theriva Biologics Inc (TOVX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Theriva Biologics Inc (TOVX) Cash Flow - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

TOVX|Theriva Biologics Inc|Price:0.214|Chg%:-0.009 - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Theriva Biologics Inc (TOVX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jul 27, 2026
pulisher
Jul 26, 2026

Theriva Biologics Inc (TOVX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jul 26, 2026
pulisher
Jul 26, 2026

Theriva Biologics Inc (TOVX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jul 26, 2026
pulisher
Jul 25, 2026

Theriva Biologics, Inc. Revenue Breakdown – BOATS:TOVX - TradingView

Jul 25, 2026
pulisher
Jul 24, 2026

Theriva Biologics Inc (TOVX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jul 24, 2026
pulisher
Jul 23, 2026

TOVX|Theriva Biologics Inc|Price:0.223|Chg%:-0.001 - TradingKey

Jul 23, 2026
pulisher
Jul 22, 2026

Theriva Biologics (TOVX) Proxy Filing Summary - Quartr

Jul 22, 2026
pulisher
Jul 20, 2026

Theriva Biologics (TOVX) Slides 5% as Selling Pressure Mounts Near Key SupportPCR Extreme - vinanet.vn

Jul 20, 2026
pulisher
Jul 16, 2026

Theriva Biologics (TOVX) Declines 5.6% as Stock Tests Key Support LevelsAI Trade Signals - dars.gov.et

Jul 16, 2026
pulisher
Jul 07, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jul 07, 2026
pulisher
Jul 07, 2026

Theriva Biologics (TOVX) Secures Approval for VIRAGE2 Clinical T - GuruFocus

Jul 07, 2026
pulisher
Jul 07, 2026

Theriva Biologics Gets Spain Approval for Phase 2a Trial of Pancreatic Cancer Therapy - Moomoo

Jul 07, 2026
pulisher
Jul 07, 2026

Theriva Biologics launches VIRAGE2 metastatic pancreatic trial - TipRanks

Jul 07, 2026
pulisher
Jul 07, 2026

Theriva Biologics cleared to start VIRAGE2 trial | TOVX 8-K Filing - Stock Titan

Jul 07, 2026

Theriva Biologics Inc Azioni (TOVX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$97.64
price up icon 0.76%
$56.66
price down icon 0.87%
$35.78
price up icon 0.17%
$219.89
price up icon 0.08%
ONC ONC
$361.65
price up icon 1.00%
$207.68
price up icon 0.50%
Capitalizzazione:     |  Volume (24 ore):